Icecure Medical Ltd

IceCure Medical Ltd. is a commercial stage medical device company. It is engaged in the research, development, and marketing of cryoablation systems, disposables, and technologies based on liquid nitrogen for treating tumors. The company was founded in 2006 and is headquartered in Caesarea, Israel.

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Icecure Medical reports revenue growth and regulatory milestones in Q1

Icecure Medical Ltd (ICCM) demonstrated strong revenue growth and regulatory progress in Q1 2024, despite a net loss, reflecting a resilient business outlook.
The company's focus on product development, market acceptance, and strategic planning underscores a commitment to long-term success and sustainability.
Addressing cost management, optimizing pricing strategies, and seizing market opportunities will be crucial for Icecure to enhance profitability and drive growth.

Icecure Medical reports robust Q2 sales growth and FDA progress

Icecure Medical's Q2 2024 performance showcased strong sales growth and improved financial metrics.
While facing challenges such as regulatory processes and leadership continuity, the company's strengths lie in its product acceptance and fundraising success.
Opportunities in FDA approvals and market expansion present avenues for future growth and profitability for Icecure Medical.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

IceCure Medical Ltd. engages in the development and marketing of therapy for the treatment of tumors. Its product, ProSense Cryoablation System, provides invasive treatment option to destroy tumors by freezing them. The company was founded in 2006 and is headquartered in Caesarea, Israel.

Medtronic

Shanghai Medtronic to exclusively distribute IceSense3 cryoablation systems with a minimum purchase target of $3.5 million in the first 3 years of the contract   First IceSense3 systems to be delivered in 2022 CAESAREA, Israel , June 13, 2022 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ: ICCM) (TASE: ICCM) ("IceCure" or the "Company"), developer of minimally-invasive cryoablation technology, the ProSense® System (marketed under the brand name IceSense3 in China), that destroys tumors by freezing as an alternative to surgical tumor removal today announced that its wholly-owned subsidiary, IceCure (Shanghai) MedTech Co., Ltd.

IceCure Medical, Shanghai Medtronic & Turing Medical Sign Distribution Agreement in Mainland China

Regulatory filing submitted by KTRFIOS, IceCure's distributor in Brazil Filing includes breast and other cancers, benign tumors, palliative intervention, and other indications CAESAREA, Israel , June 9, 2022 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ: ICCM) (TASE: ICCM) ("IceCure" or the "Company"), developer of minimally-invasive cryoablation technology, the ProSense® System, that destroys tumors by freezing as an alternative to surgical tumor removal ("ProSense"), today announced that KTRFIOS IMPORTACAO E EXPORTACAO LTDA.

IceCure Medical's ProSense® Cryoablation System Submitted for Regulatory Approval in Brazil

IceCure Medical Ltd. (NASDAQ:ICCM ) Q1 2022 Earnings Conference Call May 18, 2022 8:30 AM ET Company Participants Eyal Shamir - Chief Executive Officer Ronen Tsimerman - Chief Financial Officer and Chief Operating Officer Richard Fine - Investigator of ICE3 Clinical Trial Conference Call Participants Ben Haynor - Alliance Global Partners Kemp Dolliver - Brookline Capital Markets Operator Welcome to IceCure's First Quarter 2022 Results Conference Call.

IceCure Medical Ltd.'s (ICCM) CEO Eyal Shamir on Q1 2022 Results - Earnings Call Transcript

Conference call scheduled for 8:30 am ET today hosted by management with guest Dr. Richard Fine Increased commercial activity in the U.S. and globally with several new ProSense® System installations during Q1 Resumption of in-person medical conferences and practitioner site visits boosts ProSense® hands-on demos, trainings, and sales opportunities  American Society of Breast Surgeons' former President presented IceCure's ICE3 trial clinical publication in her speech "Best Papers of 2021" at ASBrS following a thorough literature review of thousands of breast cancer articles published yearly CAESAREA, Israel , May 18, 2022 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ: ICCM) (TASE: ICCM) ("IceCure" or the "Company"), developer of minimally-invasive cryoablation technology, the ProSense® System, that destroys tumors by freezing as an alternative to surgical tumor removal ("ProSense"), today reported financial results as of and for the quarter ended March 31, 2022 and operational highlights.

IceCure Medical Reports First Quarter 2022 Financial Results and Operational Highlights

CAESAREA, Israel , May 11, 2022 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ: ICCM) (TASE: ICCM) ("IceCure" or the "Company"), developer of minimally-invasive cryoablation technology, the ProSense® System, that destroys tumors by freezing as an alternative to surgical tumor removal ("ProSense"), today announced it will report its business and financial results for the first quarter ended March 31, 2022 on Wednesday, May 18, 2022 with a press release issued at 7:00 am ET.

IceCure Medical to Report Q1 2022 Results and Conduct Conference Call May 18, 2022

CAESAREA, Israel , April 27, 2022 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ: ICCM) (TASE: ICCM) ("IceCure" or the "Company"), developer of minimally-invasive cryoablation technology, the ProSense® System, that destroys tumors by freezing as an alternative to surgical tumor removal, today announced it hosted three key ProSense® System events at the European Conference on Interventional Oncology (ECIO) from April 24 to 27, 2022 in Vienna, Austria.

IceCure Medical Presents ICE3 Breast Cancer Trial Interim Data, Hosts Cryoablation Symposium & Conducts Hands-On ProSense® Training Sessions at the European Conference on Interventional Oncology

CAESAREA, Israel, Jan. 31, 2022 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ: ICCM) (TASE: ICCM) ("IceCure" or the "Company"), developer of minimally-invasive cryoablation technology, the ProSense® System, that destroys tumors by freezing as an alternative to surgical tumor removal, today announced preliminary unaudited year-end financial results for the twelve months ended December 31, 2021.

IceCure Medical Announces Preliminary Unaudited 2021 Year-End Financial Results

CAESAREA, Israel, Dec. 20, 2021 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ: ICCM) (TASE: ICCM) ("IceCure" or the "Company"), developer of minimally-invasive cryoablation technology, the ProSense® System, that destroys tumors by freezing as an alternative to surgical tumor removal, today announced that it received notification from the European Patent Office (the "EPO") of an intention to grant a patent for IceCure's application entitled "Cryogen Pump".

IceCure Medical Receives Notice of Intention to Grant a European Patent Covering Its Cryogenic Pump

CAESAREA, Israel, Dec. 13, 2021 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ: ICCM) (TASE: ICCM) (the "Company" or "IceCure"), developer of minimally-invasive cryoablation technology, the ProSense® System, that destroys tumors by freezing as an alternative to surgical tumor removal, today announced the closing of its underwritten public offering of 3,892,152 shares of the Company's ordinary shares, inclusive of 578,325 shares offered pursuant to the underwriters' over-allotment option, at a price to the public of $3.45 per share, before underwriting discounts and commissions, and to certain investors in lieu of ordinary shares, pre-funded warrants to purchase up to an aggregate of 1,034,000 ordinary shares at a price to the public of $3.449 per pre-funded warrant, which represents the per share public offering price for the Ordinary Shares less the $0.001 per share exercise price for each such pre-funded warrant.

IceCure Medical Ltd. Closes $17 Million Underwritten Public Offering and Partial Exercise of Over-Allotment Option

CAESAREA, Israel, Dec. 9, 2021 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ: ICCM) (TASE: ICCM) (the "Company" or "IceCure"), developer of minimally-invasive cryoablation technology, the ProSense® System, that destroys tumors by freezing as an alternative to surgical tumor removal, today announced the pricing of an underwritten public offering of 3,313,827 shares of the Company's ordinary shares (the "Ordinary Shares") at a price to the public of $3.45 per share, before underwriting discounts and commissions, and to certain investors in lieu of Ordinary Shares, pre-funded warrants to purchase up to an aggregate of 1,034,000 Ordinary Shares at a price to the public of $3.449 per pre-funded warrant, which represents the per share public offering price for the Ordinary Shares less the $0.001 per share exercise price for each such pre-funded warrant.

IceCure Medical Ltd. Announces Pricing of $15 Million Underwritten Public Offering

CAESAREA, Israel, Dec. 2, 2021 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ: ICCM) (TASE: ICCM) ("IceCure" or the "Company"), developer of minimally-invasive cryoablation technology, the ProSense® System, that destroys tumors by freezing as an alternative to surgical tumor removal, today announced that interim data from the ICE3 Clinical Trial on cryoablation of small, low-risk breast cancer was featured by Co-Primary Investigator, Dr. Kenneth Tomkovich at the Radiologists Society of North America (RSNA), which was held from November 29 th through December 2 nd.

IceCure Medical's Interim Results of the ICE3 Clinical Trial for Early-Stage Breast Cancer Cryoablation featured at the 2021 Annual Meeting of the Radiological Society of North America

CAESAREA, Israel, Nov. 29, 2021 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ: ICCM) (TASE: ICCM) ("IceCure" or the "Company"), developer of minimally-invasive cryoablation technology, the ProSense® System, that destroys tumors by freezing as an alternative to surgical tumor removal, today announced the appointment of Mrs.

IceCure Medical Announces Appointment of Merav Nir Dotan to Vice President Human Resources

CAESAREA, Israel, Nov. 23, 2021 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ: ICCM) (TASE: ICCM) ("IceCure" or the "Company"), developer of next-generation, minimally-invasive cryoablation technology with ProSense® that destroys tumors by freezing as an alternative to surgical tumor removal, today reported its financial results as of and for the nine-month period ended September 30, 2021.

IceCure Medical Reports Financial Results as of and for the first Nine Months of 2021 and Recent Corporate Developments

CAESAREA, Israel, Nov. 1, 2021 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ: ICCM) (TASE: ICCM) ("IceCure" or the "Company"), developer of the next generation minimally invasive cryoablation technology that destroys tumors by freezing, today announced that a peer reviewed article titled, "VAB and MRI Following Percutaneous Ultra-Sound Guided Cryoablation for Primary Early-Stage Breast Cancer: A Pilot Study in Japan," was published in the Journal of Cancer Therapy by lead author Dr. Hisanori Kawamoto, MD, PhD.

IceCure Medical Announces New Independent Data Published in the Journal of Cancer Therapy Showing that Percutaneous Cryoablation Presents a Potential Substitute for Lumpectomy for Tumors

CAESAREA, Israel, Oct. 20, 2021 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM) (TASE: ICCM) ("IceCure" or the "Company"), developer of the next generation minimally invasive cryoablation technology that destroys tumors by freezing, today announced that it has entered into an initial distribution agreement with Mobile SCANMED Systems SP.

IceCure Medical Enters into an Exclusive Agreement in Poland for Distribution of the ProSense™ Cryoablation System

CAESAREA, Israel, Oct. 12, 2021 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ: ICCM) (TASE: ICCM) ("IceCure" or the "Company"), developer of the next generation minimally invasive cryoablation technology that destroys tumors by freezing, today announced the advancement of its regulatory strategy in China with the submission of an amendment to the registration certificate for the IceSense3® system, which was granted by China's National Medical Products Administration ("NMPA").

News for Icecure Medical Ltd Stock (ICCM)